Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-10-07

GLAUKOS Corp (GKOS)

CEO Thomas Burns was paid $12,034,087 in fiscal year 2025, ↑ up 33.3% from fiscal year 2024, the 52nd percentile of its disclosed peer group (SEC filing 0001193125-26-157829 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$12,034,087 ↑
Thomas Burns total, FY2025
52nd
CEO pay percentile vs peers
67.4:1
CEO-to-median pay ratio
91.77%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Thomas Burns (Chairman of the Board & Chief Executive Officer), FY2025 total compensation $12,034,087 (base salary $850,000) [exec_comp, SEC accession 0001193125-26-157829, filed 2026-04-16]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

GKOS's next annual pay disclosure, estimated April 16, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Thomas Burns$850,000$0$7,649,947$3,527,497$0$0$6,643$12,034,087
Chairman of the Board & Chief Executive Officer
Joseph Gilliam584,85006,500,0130689,006011,7507,785,619
President and Chief Operating Officer
Tomas Navratil499,40002,399,9300504,290011,7503,415,370
Chief Development Officer
Alex Thurman486,200002,435,4810015,7502,937,431
Senior Vice President & Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Thomas Burns$12,034,087$9,030,345$8,654,684↑ +3,003,742
Joseph Gilliam7,785,6194,163,6524,179,081↑ +3,621,967
Tomas Navratil3,415,3702,780,9752,566,156↑ +634,395
Alex Thurman2,937,4312,457,3752,359,969↑ +480,056

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read GLAUKOS Corp's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper GKOS reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the GLAUKOS Corp Peer Teardown Report

$12,034,087 Thomas Burns total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of October 7, 2026 · Source: 0001193125-26-157829 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for GKOS

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
GKOSon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order GKOS

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against GKOS
18 companies name GKOS as a compensation peer

Each company listed discloses GKOS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GKOS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Get the GLAUKOS Corp Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Alex ThurmanCFO$2,937,431
Joseph GilliamPresident$7,785,619
Thomas BurnsCEO$12,034,087
Tomas NavratilChief Development Officer$3,415,370
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Aimee S. WeisnerIndependent Director$428,989
David F. HoffmeisterIndependent Director$443,359
Denice M. TorresIndependent Director$428,989
Gilbert H. Kliman, M.DIndependent Director$428,989
Leana S. Wen, M.DIndependent Director$428,989
Marc A. StapleyIndependent Director$440,515
Mark J. FoleyLead Independent Director$489,311
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Alex ThurmanSVP & CHIEF FINANCIAL OFFICER2026-04-30D10,000$39$386,800Derivative, Class A CommonForm 4 ↗
Alex ThurmanSVP & CHIEF FINANCIAL OFFICER2026-04-30D10,0001401,400,000CommonForm 4 ↗
Alex ThurmanSVP & CHIEF FINANCIAL OFFICER2026-04-30A10,00039386,800CommonForm 4 ↗
Leana WenDirector2026-05-01D1,700143243,695CommonForm 4 ↗
Joseph GilliamPRESIDENT & COO2026-05-01D19,5731442,809,508CommonForm 4 ↗
Gilbert H. KlimanDirector2026-05-11D5,00025123,450Derivative, Class A CommonForm 4 ↗
Gilbert H. KlimanDirector2026-05-11D5,000135675,000CommonForm 4 ↗
Gilbert H. KlimanDirector2026-05-11A5,00025123,450CommonForm 4 ↗
Gilbert H. KlimanDirector2026-05-14D5,00025123,450Derivative, Class A CommonForm 4 ↗
Gilbert H. KlimanDirector2026-05-14A5,00025123,450CommonForm 4 ↗
Gilbert H. KlimanDirector2026-05-14D5,000141703,800CommonForm 4 ↗
David F. HoffmeisterDirector2026-05-26D15,00025370,350Derivative, Class A CommonForm 4 ↗
David F. HoffmeisterDirector2026-05-26A15,00025370,350CommonForm 4 ↗
Marc A. StapleyDirector2026-05-28A2,98700Derivative, Class A CommonForm 4 ↗
Gilbert H. KlimanDirector2026-05-28A2,98700Derivative, Class A CommonForm 4 ↗
Gilbert H. KlimanDirector2026-05-28A1,87800CommonForm 4 ↗
David F. HoffmeisterDirector2026-05-28A2,98700Derivative, Class A CommonForm 4 ↗
Mark J. FoleyDirector2026-05-28A2,98700Derivative, Class A CommonForm 4 ↗
Mark J. FoleyDirector2026-05-28A1,87800CommonForm 4 ↗
Denice M. TorresDirector2026-05-28A2,98700Derivative, Class A CommonForm 4 ↗
Denice M. TorresDirector2026-05-28A1,87800CommonForm 4 ↗
Aimee S. WeisnerDirector2026-05-28A2,98700Derivative, Class A CommonForm 4 ↗
Aimee S. WeisnerDirector2026-05-28A1,87800CommonForm 4 ↗
Leana WenDirector2026-05-28A2,98700Derivative, Class A CommonForm 4 ↗
Denice M. TorresDirector2026-05-28A2,98700Derivative, Class A CommonForm 4 ↗
David F. HoffmeisterDirector2026-05-28A2,98700Derivative, Class A CommonForm 4 ↗
Gilbert H. KlimanDirector2026-05-28A2,98700Derivative, Class A CommonForm 4 ↗
Aimee S. WeisnerDirector2026-05-28A2,98700Derivative, Class A CommonForm 4 ↗
Marc A. StapleyDirector2026-05-28A2,98700Derivative, Class A CommonForm 4 ↗
Leana WenDirector2026-05-28A2,98700Derivative, Class A CommonForm 4 ↗
Mark J. FoleyDirector2026-05-28A2,98700Derivative, Class A CommonForm 4 ↗
Leana WenDirector2026-05-28A1,87800CommonForm 4 ↗
David F. HoffmeisterDirector2026-05-28A1,87800CommonForm 4 ↗
Marc A. StapleyDirector2026-05-28A1,87800CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-06-16D1,537131200,855CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-06-25D48314368,861CommonForm 4 ↗
Joseph GilliamPRESIDENT & COO2026-06-25D1,056143150,554CommonForm 4 ↗
Thomas William BurnsDirector2026-06-25D4,059143578,692CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-07-01D71613999,567CommonForm 4 ↗
Alex ThurmanSVP & CHIEF FINANCIAL OFFICER2026-07-06D10,00039386,800Derivative, Class A CommonForm 4 ↗
Alex ThurmanSVP & CHIEF FINANCIAL OFFICER2026-07-06D10,0001501,500,000CommonForm 4 ↗
Alex ThurmanSVP & CHIEF FINANCIAL OFFICER2026-07-06A10,00039386,800CommonForm 4 ↗
Alex ThurmanSVP & CHIEF FINANCIAL OFFICER2026-07-09D10,00000Derivative, Class A CommonForm 4 ↗
Alex ThurmanSVP & CHIEF FINANCIAL OFFICER2026-07-09A10,00039386,800CommonForm 4 ↗
Alex ThurmanSVP & CHIEF FINANCIAL OFFICER2026-07-09D10,0001551,550,000CommonForm 4 ↗
Alex ThurmanSVP & CHIEF FINANCIAL OFFICER2026-07-16D10,00000Derivative, Class A CommonForm 4 ↗
Alex ThurmanSVP & CHIEF FINANCIAL OFFICER2026-07-16D10,0001601,600,000CommonForm 4 ↗
Alex ThurmanSVP & CHIEF FINANCIAL OFFICER2026-07-16A10,00039386,800CommonForm 4 ↗
Leana WenDirector2026-07-31D52516888,006CommonForm 4 ↗
Alex ThurmanSVP & CHIEF FINANCIAL OFFICER2026-08-07D20,00000Derivative, Class A CommonForm 4 ↗
Alex ThurmanSVP & CHIEF FINANCIAL OFFICER2026-08-07A20,00034676,200CommonForm 4 ↗
Alex ThurmanSVP & CHIEF FINANCIAL OFFICER2026-08-07D20,0001803,602,600CommonForm 4 ↗
Joseph GilliamPRESIDENT & COO2026-08-11D10,00000Derivative, Class A CommonForm 4 ↗
Joseph GilliamPRESIDENT & COO2026-08-11D10,00000Derivative, Class A CommonForm 4 ↗
Joseph GilliamPRESIDENT & COO2026-08-11D20,00000Derivative, Class A CommonForm 4 ↗
Joseph GilliamPRESIDENT & COO2026-08-11D27,9631795,002,301CommonForm 4 ↗
Joseph GilliamPRESIDENT & COO2026-08-11A10,00048484,600CommonForm 4 ↗
Joseph GilliamPRESIDENT & COO2026-08-11A20,000551,103,600CommonForm 4 ↗
Joseph GilliamPRESIDENT & COO2026-08-11A20,000551,103,600CommonForm 4 ↗
Joseph GilliamPRESIDENT & COO2026-08-11A10,00048484,600CommonForm 4 ↗
Joseph GilliamPRESIDENT & COO2026-08-11D20,00000Derivative, Class A CommonForm 4 ↗
Joseph GilliamPRESIDENT & COO2026-08-11D32,0371805,782,358CommonForm 4 ↗
Gilbert H. KlimanDirector2026-08-19D2,500190475,000CommonForm 4 ↗
Gilbert H. KlimanDirector2026-08-19D2,50000Derivative, Class A CommonForm 4 ↗
Gilbert H. KlimanDirector2026-08-19A2,5002664,425CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-08-28D6,0911811,103,628CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-08-28D101831,825CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-08-28D7,6431801,377,651CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-09-16D23417140,002CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-09-16D12016820,206CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-09-16D46016776,967CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-09-16D4172688CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-09-16D19116631,744CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-09-16D10316316,810CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-09-16D34516556,787CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-09-25D1,083155167,735CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-09-25D22915435,321CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-09-25D13615320,769CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-09-25D16715225,334CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-10-05D31216651,667CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-10-05D32716553,883CommonForm 4 ↗
Tomas NavratilCHIEF DEVELOPMENT OFFICER2026-10-05D888164145,570CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Joseph GilliamOTHER—————$6,500,013
Thomas BurnsOTHER—————7,649,947
Tomas NavratilOTHER—————2,399,930
03b

Vehicle mix — grant-date fair value by award type

Grant-level vehicle detail not disclosed.

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Joseph GilliamPSU54,930—$6,202,146
Tomas NavratilPSU24,844—2,805,136
Joseph GilliamPSU36,232—4,090,955
Thomas BurnsOption21,01685.78—
Joseph GilliamPSU37,889—4,277,991
Thomas BurnsPSU15,417—1,740,733
Alex ThurmanOption19,84996.6—
Thomas BurnsRSU15,957—1,801,705
Tomas NavratilRSU5,135—579,793
Tomas NavratilRSU8,307—937,943
Thomas BurnsPSU79,192—8,941,569
Joseph GilliamRSU43,587—4,508,417
Thomas BurnsPSU92,194—10,409,568
Thomas BurnsPSU13,584—1,533,769
Joseph GilliamRSU10,318—1,165,005
Joseph GilliamRSU6,558—740,464
Thomas BurnsOption2,63155.18—
Tomas NavratilRSU27,668—2,965,844
Joseph GilliamRSU18,116—2,045,478
Alex ThurmanRSU4,531—511,595
Tomas NavratilRSU12,422—1,402,568
Joseph GilliamOption8,63785.78—
Alex ThurmanRSU17,460—1,776,504
Tomas NavratilRSU11,694—1,320,370
Thomas BurnsRSU39,596—4,470,784
Joseph GilliamOption11,48648.46—
Thomas BurnsRSU71,287—6,891,404
Tomas NavratilPSU23,997—2,709,445
Joseph GilliamPSU3,886—438,768
Thomas BurnsPSU24,290—2,742,584
Tomas NavratilPSU23,386—2,640,513
Alex ThurmanPSU21,470—2,424,121
Joseph GilliamRSU13,592—1,534,673
Tomas NavratilPSU1,948—219,949
Joseph GilliamRSU9,062—1,023,190
Tomas NavratilPSU6,677—753,900
Alex ThurmanRSU5,503—621,344
Thomas BurnsRSU5,211—588,374
Alex ThurmanRSU3,717—419,686
Thomas BurnsOption13,54848.46—
Alex ThurmanOption6,12648.46—
Alex ThurmanOption4,89485.78—
05

Incentive-plan design — the Compensation Discussion & Analysis

The executive compensation program is designed to attract and retain top-caliber executives, reward both near-term results and long-term growth, and align pay with performance and shareholder interests. A significant portion of compensation is variable, with 93% of the CEO's and 85% of other NEOs' target compensation tied to performance-based annual bonuses and equity grants.

CEO STI target (% of salary)100%
CEO LTI target (% of salary)—
Independent consultantFrederic W. Cook & Co., Inc.
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-2847,653,7944,272,83085,86191.77%Passed
20252025-05-2948,971,1691,143,78957,53497.72%Passed
20242024-05-3043,205,8601,952,506140,07695.38%Passed
20232023-06-0137,101,2963,742,56830,09490.84%Passed
20222022-06-0236,804,6632,718,20733,04693.12%Passed
20212021-06-0338,105,9632,834,49757,48493.08%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-2891.77%a
20252025-05-2997.72%b
20242024-05-3095.38%c

a. Approved under the standard stated in the filing — “What effect do withhold votes, abstentions and broker non-votes have on the proposals? For Proposal 1 (election of directors), shares voted "WITHHOLD" will not be counted in determining the outcome of a director nominee's election.”.

b. Approved under the standard stated in the filing — “What effect do withhold votes, abstentions and broker non-votes have on the proposals? For Proposal 1 (election of directors), shares voted "WITHHOLD" will not be counted in determining the outcome of a director nominee's election.”.

c. Approved under the standard stated in the filing — “Abstentions with respect to any other proposal at the Annual Meeting will have the same effect as a vote "AGAINST" the proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)67.4 : 1
CEO total compensation$12,033,637
Median employee compensation$178,462
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Mark J. FoleyIndependent · Lead Independent Director · Compensation, Nominating and Governance (Chair)$0$329,310$160,001$0$0$489,311
David F. HoffmeisterIndependent · Audit (Chair)0283,358160,00100443,359
Marc A. StapleyIndependent · Audit · Compensation, Nominating and Governance0280,514160,00100440,515
Denice M. TorresIndependent · Compensation, Nominating and Governance0268,988160,00100428,989
Leana S. Wen, M.DIndependent · Audit0268,988160,00100428,989
Aimee S. WeisnerIndependent · Audit0268,988160,00100428,989
Gilbert H. Kliman, M.DIndependent · Compensation, Nominating and Governance0268,988160,00100428,989
Thomas W. BurnsEmployee director · Board Chair000—00
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$360,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)12,500 / 12,500
Stock ownership guideline$6
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$0
Equity awards (grant-date value)$1,969,134
All other compensation$0
Total cost of the board$1,969,134

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies GLAUKOS Corp names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including GLAUKOS Corp.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Halozyme2025Helen Torley$1,000,000$19,350,145$1,650,014$1,147,500$23,166,223
2Madrigal Pharmaceuticals2025Bill Sibold918,53112,297,8504,537,1461,438,81419,206,341
3PROCEPT BioRobotics2025Larry Wood304,8307,217,2517,226,599243,86416,783,853
4Exact Sciences2024Kevin Conroy1,083,36813,496,1380712,32915,539,378
5Natera2025Steven Chapman853,71012,979,55801,114,15114,957,319
6BridgeBio Pharmaceuticals2025Neil Kumar1,044,00010,606,2751,874,992014,944,585
7Insmed2025William Lewis854,5502,999,9409,000,0331,495,46314,467,393
8Blueprint Medicines2024Kathryn Haviland821,3637,472,4804,315,144854,21713,477,004
9Ionis Pharmaceuticals2025Brett Monia1,051,7768,444,8381,438,105013,350,777
10Haemonetics2026Christopher Simon1,100,0087,561,9871,504,9681,834,25012,044,701
11GLAUKOS Corp2025Thomas Burns850,0007,649,9473,527,497012,034,087
12Ultragenyx Pharmaceuticals2025Emil Kakkis861,1008,364,9381,847,356299,66311,405,535
13Vericel2025Dominick Colangelo860,0003,964,6305,456,287860,00011,156,368
14iRhythm Technologies2025Quentin Blackford700,0038,919,45701,350,00011,003,163
15Apellis Pharmaceuticals2024Cedric Francois793,1934,779,8324,787,768010,957,451
16TransMedics Group2025Waleed Hassanein776,9234,364,0134,360,1471,400,00010,915,533
17Intra-Cellular Therapeutics2023Sharon Mates891,6537,749,9840010,086,413
18Inspire Medical2025Timothy Herbert750,5725,999,6550961,5577,711,784
19STAAR Surgical2025Stephen Farrell580,0006,836,000007,522,385
20Repligen2025Olivier Loeillot860,0003,374,8531,095,626774,0006,114,771
21Inari Medical2023Andrew Hykes700,0002,606,744937,488826,0005,083,365
22Lantheus2025Mary Anne Heino100,000749,963749,99902,173,930
—Axonics——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
GLAUKOS Corp177.5%RSU 50 · PRSU 50NoFrederic W. Cook & Co., Inc.
Apellis Pharmaceuticals90.74%RSU 50 · PSU 50not disclosedPay Governance
Axonicsnot disclosednot disclosednot disclosednot disclosed
Blueprint Medicines130%RSU 37 · Options 32 · PSU 31Yes — Relative Total Stockholder Return (rTSR)Aon
BridgeBio Pharmaceuticals135%RSU 50 · PSU 35 · Options 15NoAon Talent Solutions
Exact Sciences47%PSU 60 · RSU 40NoAon
Haemonetics133.4%PSU 60 · RSU 20 · Options 20Yes — Relative Total Shareholder Return (rTSR)Pearl Meyer & Partners, LLC
Halozyme127.5%PSU 50 · RSU 35 · Option 15NoF.W. Cook & Co., Inc.
Inari Medical118%RSU 75 · Option 25not disclosedFW Cook
Insmed175%Options 75 · RSU 25NoWillis Towers Watson (WTW)
Inspire Medical111.4%PSU 50 · RSU 50NoAon
Intra-Cellular Therapeuticsnot disclosedRSU 75 · PRSU 25Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology IndexAon Consulting, Inc.
Ionis Pharmaceuticalsnot disclosedPRSU 40 · Option 30 · RSU 30Yes — Relative TSRAon
iRhythm Technologies173%RSU 50 · PSU 50Yes — Relative TSRAon and Mercer
Lantheus47%PSU 50 · RSU 25 · Options 25Yes — relative Total Shareholder Return (rTSR) against the S&P 400 Health Care IndexPearl Meyer
Madrigal Pharmaceuticals195%PSU 33 · RSU 33 · Options 33Yes — Relative TSR vs Nasdaq Biotechnology IndexCompensia
Natera131.1%PSU 50 · RSU 50NoAon
PROCEPT BioRobotics80%RSU 50 · PSU 25 · Options 25Yes — Relative TSRAlpine
Repligen100%RSU 50 · PSU 25 · Options 25NoMeridian Compensation Partners, LLC
STAAR Surgical135%RSU 50 · PSU 50NoSemler Brossy
TransMedics Group175%Options 50 · RSU 50not disclosedPearl Meyer
Ultragenyx Pharmaceuticals44%PSU 60 · RSU 20 · Options 20Yes — Relative TSRAon's Human Capital Solutions Practice
Vericel100%Options 58 · RSU 42not disclosedFW Cook

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at GLAUKOS Corp in fiscal 2025?
As disclosed, Thomas Burns (Chairman of the Board & Chief Executive Officer) was the highest-paid executive at GLAUKOS Corp in fiscal 2025, with total compensation of $12,034,087.
How does GLAUKOS Corp's chief executive pay compare to its disclosed peer group?
As disclosed, Thomas Burns's total compensation ranked at the 52nd percentile of GLAUKOS Corp's disclosed peer group.
What is GLAUKOS Corp's CEO-to-median employee pay ratio?
As disclosed, GLAUKOS Corp's CEO-to-median employee pay ratio was 67.4:1.
How did shareholders vote on GLAUKOS Corp's executive compensation?
As disclosed, 91.77% of shareholders supported GLAUKOS Corp's executive compensation in the latest say-on-pay vote.
How much does GLAUKOS Corp spend in total on board compensation for fiscal 2025?
As disclosed, GLAUKOS Corp reported total board compensation of $1,969,134 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Thomas BurnsDEF 14A2026-04-160001193125-26-157829Section “Summary Compensation Table for Fiscal Years 2025, 2024 and 2023”. As printed: 12,034,087. Filing ↗machine: r6 · c38 · span 1876942–1876952
2Section 01, Joseph GilliamDEF 14A2026-04-160001193125-26-157829Section “Summary Compensation Table for Fiscal Years 2025, 2024 and 2023”. As printed: 7,785,619. Filing ↗machine: r11 · c38 · span 1948374–1948383
3Section 01, Tomas NavratilDEF 14A2026-04-160001193125-26-157829Section “Summary Compensation Table for Fiscal Years 2025, 2024 and 2023”. As printed: 3,415,370. Filing ↗machine: r22 · c38 · span 2104168–2104177
4Section 01, Alex ThurmanDEF 14A2026-04-160001193125-26-157829Section “Summary Compensation Table for Fiscal Years 2025, 2024 and 2023”. As printed: 2,937,431. Filing ↗machine: r17 · c38 · span 2032144–2032153
5Section 03, Joseph Gilliam OTHERDEF 14A2026-04-160001193125-26-157829Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t93 · r11 · c17 · span 1940497–1940506
6Section 03, Thomas Burns OTHERDEF 14A2026-04-160001193125-26-157829Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t93 · r6 · c18 · span 1869064–1869073
7Section 03, Tomas Navratil OTHERDEF 14A2026-04-160001193125-26-157829Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t93 · r22 · c17 · span 2096291–2096300
8Section 07, pay ratioDEF 14A2026-04-160001193125-26-157829Section “CEO Pay Ratio”. As printed: 67.4 : 1. Filing ↗
9Section 08, Mark J. FoleyDEF 14A2026-04-160001193125-26-157829Section “Director Compensation”. As printed: 489,311. Filing ↗machine: span 637926–638173
10Section 08, David F. HoffmeisterDEF 14A2026-04-160001193125-26-157829Section “Director Compensation”. As printed: 443,359. Filing ↗machine: span 645384–645631
11Section 08, Marc A. StapleyDEF 14A2026-04-160001193125-26-157829Section “Director Compensation”. As printed: 440,515. Filing ↗machine: span 660298–660545
12Section 08, Denice M. TorresDEF 14A2026-04-160001193125-26-157829Section “Director Compensation”. As printed: 428,989. Filing ↗machine: span 667752–667999
13Section 08, Leana S. Wen, M.DDEF 14A2026-04-160001193125-26-157829Section “Director Compensation”. As printed: 428,989. Filing ↗machine: span 682678–682925
14Section 08, Aimee S. WeisnerDEF 14A2026-04-160001193125-26-157829Section “Director Compensation”. As printed: 428,989. Filing ↗machine: span 675206–675453
15Section 08, Gilbert H. Kliman, M.DDEF 14A2026-04-160001193125-26-157829Section “Director Compensation”. As printed: 428,989. Filing ↗machine: span 652845–653092
16Section 08, Thomas W. BurnsDEF 14A2026-04-160001193125-26-157829Section “Director Compensation”. As printed: 0. Filing ↗
17Section 02, Alex Thurman 2026-04-30Form 42026-05-040001920061-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Alex Thurman 2026-04-30Form 42026-05-040001920061-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Alex Thurman 2026-04-30Form 42026-05-040001920061-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Leana Wen 2026-05-01Form 42026-05-040001847598-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Joseph Gilliam 2026-05-01Form 42026-05-040001705850-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Gilbert H. Kliman 2026-05-11Form 42026-05-130001293171-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Gilbert H. Kliman 2026-05-11Form 42026-05-130001293171-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Gilbert H. Kliman 2026-05-11Form 42026-05-130001293171-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Gilbert H. Kliman 2026-05-14Form 42026-05-180001293171-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Gilbert H. Kliman 2026-05-14Form 42026-05-180001293171-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Gilbert H. Kliman 2026-05-14Form 42026-05-180001293171-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, David F. Hoffmeister 2026-05-26Form 42026-05-280001305975-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, David F. Hoffmeister 2026-05-26Form 42026-05-280001305975-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Marc A. Stapley 2026-05-28Form 42026-06-010001539796-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Gilbert H. Kliman 2026-05-28Form 42026-06-010001293171-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Gilbert H. Kliman 2026-05-28Form 42026-06-010001293171-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, David F. Hoffmeister 2026-05-28Form 42026-06-010001305975-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Mark J. Foley 2026-05-28Form 42026-06-010001529196-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Mark J. Foley 2026-05-28Form 42026-06-010001529196-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Denice M. Torres 2026-05-28Form 42026-06-010001820278-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Denice M. Torres 2026-05-28Form 42026-06-010001820278-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Aimee S. Weisner 2026-05-28Form 42026-06-010001227308-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Aimee S. Weisner 2026-05-28Form 42026-06-010001227308-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Leana Wen 2026-05-28Form 42026-06-010001847598-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Denice M. Torres 2026-05-28Form 42026-06-230001820278-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, David F. Hoffmeister 2026-05-28Form 42026-06-230001305975-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Gilbert H. Kliman 2026-05-28Form 42026-06-230001293171-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Aimee S. Weisner 2026-05-28Form 42026-06-230001227308-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Marc A. Stapley 2026-05-28Form 42026-06-230001539796-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Leana Wen 2026-05-28Form 42026-06-230001847598-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Mark J. Foley 2026-05-28Form 42026-06-230001529196-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Leana Wen 2026-05-28Form 42026-06-010001847598-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, David F. Hoffmeister 2026-05-28Form 42026-06-010001305975-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Marc A. Stapley 2026-05-28Form 42026-06-010001539796-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Tomas Navratil 2026-06-16Form 42026-06-180001920053-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Tomas Navratil 2026-06-25Form 42026-06-290001920053-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Joseph Gilliam 2026-06-25Form 42026-06-290001705850-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Thomas William Burns 2026-06-25Form 42026-06-290001644557-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Tomas Navratil 2026-07-01Form 42026-07-080001920053-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Alex Thurman 2026-07-06Form 42026-07-080001920061-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Alex Thurman 2026-07-06Form 42026-07-080001920061-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Alex Thurman 2026-07-06Form 42026-07-080001920061-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Alex Thurman 2026-07-09Form 42026-07-130001920061-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Alex Thurman 2026-07-09Form 42026-07-130001920061-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Alex Thurman 2026-07-09Form 42026-07-130001920061-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Alex Thurman 2026-07-16Form 42026-07-210001920061-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Alex Thurman 2026-07-16Form 42026-07-210001920061-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Alex Thurman 2026-07-16Form 42026-07-210001920061-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Leana Wen 2026-07-31Form 42026-08-030001847598-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Alex Thurman 2026-08-07Form 42026-08-110001920061-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Alex Thurman 2026-08-07Form 42026-08-110001920061-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Alex Thurman 2026-08-07Form 42026-08-110001920061-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Joseph Gilliam 2026-08-11Form 42026-08-130001705850-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Joseph Gilliam 2026-08-11Form 42026-08-130001705850-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Joseph Gilliam 2026-08-11Form 42026-08-130001705850-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Joseph Gilliam 2026-08-11Form 42026-08-130001705850-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Joseph Gilliam 2026-08-11Form 42026-08-130001705850-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Joseph Gilliam 2026-08-11Form 42026-08-130001705850-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Joseph Gilliam 2026-08-11Form 42026-08-130001705850-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Joseph Gilliam 2026-08-11Form 42026-08-130001705850-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Joseph Gilliam 2026-08-11Form 42026-08-130001705850-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Joseph Gilliam 2026-08-11Form 42026-08-130001705850-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Gilbert H. Kliman 2026-08-19Form 42026-08-200001293171-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Gilbert H. Kliman 2026-08-19Form 42026-08-200001293171-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Gilbert H. Kliman 2026-08-19Form 42026-08-200001293171-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Tomas Navratil 2026-08-28Form 42026-09-010001920053-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Tomas Navratil 2026-08-28Form 42026-09-010001920053-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Tomas Navratil 2026-08-28Form 42026-09-010001920053-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Tomas Navratil 2026-09-16Form 42026-09-180001920053-26-000028Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Tomas Navratil 2026-09-16Form 42026-09-180001920053-26-000028Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Tomas Navratil 2026-09-16Form 42026-09-180001920053-26-000028Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Tomas Navratil 2026-09-16Form 42026-09-180001920053-26-000028Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Tomas Navratil 2026-09-16Form 42026-09-180001920053-26-000028Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Tomas Navratil 2026-09-16Form 42026-09-180001920053-26-000028Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Tomas Navratil 2026-09-16Form 42026-09-180001920053-26-000028Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Tomas Navratil 2026-09-25Form 42026-09-280001920053-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Tomas Navratil 2026-09-25Form 42026-09-280001920053-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Tomas Navratil 2026-09-25Form 42026-09-280001920053-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Tomas Navratil 2026-09-25Form 42026-09-280001920053-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Tomas Navratil 2026-10-05Form 42026-10-070001193125-26-417151Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Tomas Navratil 2026-10-05Form 42026-10-070001193125-26-417151Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Tomas Navratil 2026-10-05Form 42026-10-070001193125-26-417151Insider equity transaction reported since the proxy statement. Filing ↗
99Section 06, 2026 voteForm 8-K2026-06-030001193125-26-255758Item 5.07 · say-on-pay result. As reported: 91.77% (votes for as printed: 47,653,794). Filing ↗
100Section 06, 2025 voteForm 8-K2025-06-030001558370-25-008365Item 5.07 · say-on-pay result. As reported: 97.72% (votes for as printed: 48,971,169). Filing ↗
101Section 06, 2024 voteForm 8-K2024-06-050001558370-24-008913Item 5.07 · say-on-pay result. As reported: 95.38% (votes for as printed: 43,205,860). Filing ↗
102Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
103Section 09b board cost (computed)Computed——Cash 0 + equity 1,969,134 + all other 0 = 1,969,134, summed across the director compensation table rows.machine: formula: Σ = 1,969,134
104Halozyme, Section 10b CEO totalDEF 14A2026-03-230001159036-26-000041CEO total compensation as printed in Halozyme's own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292
105Madrigal Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-280001308179-26-000352CEO total compensation as printed in Madrigal Pharmaceuticals's own proxy. As printed: 19,206,341. Filing ↗machine: r2 · c24 · span 791942–791952
106PROCEPT BioRobotics, Section 10b CEO totalDEF 14A2026-04-220001588978-26-000017CEO total compensation as printed in PROCEPT BioRobotics's own proxy. As printed: 16,783,853. Filing ↗machine: r2 · c48 · span 520911–520921
107Exact Sciences, Section 10b CEO totalDEF 14A2025-04-290001124140-25-000034CEO total compensation as printed in Exact Sciences's own proxy. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865
108Natera, Section 10b CEO totalDEF 14A2026-04-230001104659-26-047770CEO total compensation as printed in Natera's own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878
109BridgeBio Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-240001140361-26-016723CEO total compensation as printed in BridgeBio Pharmaceuticals's own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531
110Insmed, Section 10b CEO totalDEF 14A2026-04-010001104506-26-000022CEO total compensation as printed in Insmed's own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563
111Blueprint Medicines, Section 10b CEO totalDEF 14A2025-04-240001558370-25-005415CEO total compensation as printed in Blueprint Medicines's own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162
112Ionis Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-230001140361-26-016388CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. Filing ↗
113Haemonetics, Section 10b CEO totalDEF 14A2026-06-090000313143-26-000074CEO total compensation as printed in Haemonetics's own proxy. As printed: 12,044,701. Filing ↗machine: span 718173–718183
114GLAUKOS Corp (subject), Section 10b CEO totalDEF 14A2026-04-160001193125-26-157829CEO total compensation as printed in GLAUKOS Corp's own proxy. As printed: 12,034,087. Filing ↗machine: r6 · c38 · span 1876942–1876952
115Ultragenyx Pharmaceuticals, Section 10b CEO totalDEF 14A2026-03-270001308179-26-000174CEO total compensation as printed in Ultragenyx Pharmaceuticals's own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007
116Vericel, Section 10b CEO totalDEF 14A2026-03-190001308179-26-000094CEO total compensation as printed in Vericel's own proxy. As printed: 11,156,368. Filing ↗machine: t258 · r1 · c27 · span 627744–627754
117iRhythm Technologies, Section 10b CEO totalDEF 14A2026-04-170001388658-26-000030CEO total compensation as printed in iRhythm Technologies's own proxy. As printed: 11,003,163. Filing ↗machine: r2 · c21 · span 1123498–1123508
118Apellis Pharmaceuticals, Section 10b CEO totalDEF 14A2025-04-230000950170-25-056966CEO total compensation as printed in Apellis Pharmaceuticals's own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565
119TransMedics Group, Section 10b CEO totalDEF 14A2026-04-100001193125-26-150357CEO total compensation as printed in TransMedics Group's own proxy. As printed: 10,915,533. Filing ↗machine: r3 · c39 · span 572169–572179
120Intra-Cellular Therapeutics, Section 10b CEO totalDEF 14A2024-04-290001628280-24-018986CEO total compensation as printed in Intra-Cellular Therapeutics's own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603
121Inspire Medical, Section 10b CEO totalDEF 14A2026-03-200001140361-26-010490CEO total compensation as printed in Inspire Medical's own proxy. As printed: 7,711,784. Filing ↗machine: r2 · c25 · span 1164868–1164877
122STAAR Surgical, Section 10b CEO totalDEF 14A2026-05-040000718937-26-000015CEO total compensation as printed in STAAR Surgical's own proxy. As printed: 7,522,385. Filing ↗machine: r3 · c16 · span 1045477–1045486
123Repligen, Section 10b CEO totalDEF 14A2026-04-020001193125-26-140115CEO total compensation as printed in Repligen's own proxy. As printed: 6,114,771. Filing ↗machine: t16 · r4 · c2 · span 577065–577074
124Inari Medical, Section 10b CEO totalDEF 14A2024-03-130001193125-24-066805CEO total compensation as printed in Inari Medical's own proxy. As printed: 5,083,365. Filing ↗machine: r2 · c31 · span 454508–454517
125Lantheus, Section 10b CEO totalDEF 14A2026-03-200001193125-26-117649CEO total compensation as printed in Lantheus's own proxy. As printed: 2,173,930. Filing ↗machine: r3 · c39 · span 957618–957628
126Section 10a, Halozyme reciprocityDEF 14A—0001159036-26-000041Halozyme's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗
127Section 10a, iRhythm Technologies reciprocityDEF 14A—0001388658-26-000030iRhythm Technologies's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗
128Section 10a, Natera reciprocityDEF 14A—0001104659-26-047770Natera's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗
129Section 10a, Repligen reciprocityDEF 14A—0001193125-26-140115Repligen's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗
130Section 10a, Vericel reciprocityDEF 14A—0001308179-26-000094Vericel names GLAUKOS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
131Section 10a, STAAR Surgical reciprocityDEF 14A—0000718937-26-000015STAAR Surgical names GLAUKOS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
132Section 10a, Intra-Cellular Therapeutics reciprocityDEF 14A—0001628280-24-018986Intra-Cellular Therapeutics's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗
133Section 10a, Inari Medical reciprocityDEF 14A—0001193125-24-066805Inari Medical names GLAUKOS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
134Section 10a, Inspire Medical reciprocityDEF 14A—0001140361-26-010490Inspire Medical names GLAUKOS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
135Section 10a, Haemonetics reciprocityDEF 14A—0000313143-26-000074Haemonetics's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗
136Section 10a, Blueprint Medicines reciprocityDEF 14A—0001558370-25-005415Blueprint Medicines's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗
137Section 10a, Insmed reciprocityDEF 14A—0001104506-26-000022Insmed's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗
138Section 10a, Ultragenyx Pharmaceuticals reciprocityDEF 14A—0001308179-26-000174Ultragenyx Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗
139Section 10a, Exact Sciences reciprocityDEF 14A—0001124140-25-000034Exact Sciences's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗
140Section 10a, PROCEPT BioRobotics reciprocityDEF 14A—0001588978-26-000017PROCEPT BioRobotics's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗
141Section 10a, Apellis Pharmaceuticals reciprocityDEF 14A—0000950170-25-056966Apellis Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗
142Section 10a, BridgeBio Pharmaceuticals reciprocityDEF 14A—0001140361-26-016723BridgeBio Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗
143Section 10a, TransMedics Group reciprocityDEF 14A—0001193125-26-150357TransMedics Group names GLAUKOS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
144Section 10a, Ionis Pharmaceuticals reciprocityDEF 14A—0001140361-26-016388Ionis Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗
145Section 10a, Madrigal Pharmaceuticals reciprocityDEF 14A—0001308179-26-000352Madrigal Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the GLAUKOS Corp Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
GKOS Peer Teardown Report